logo

NYXH

Nyxoah·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

NYXH fundamentals

Nyxoah (NYXH) released its earnings on Nov 13, 2025: revenue was 2.30M (YoY +63.01%), beat estimates; EPS was -0.73 (YoY -32.06%), missed estimates.
Revenue / YoY
2.30M
+63.01%
EPS / YoY
-0.73
-32.06%
Report date
Nov 13, 2025
NYXH Earnings Call Summary for Q3,2025
  • U.S. Launch Success: 15 implants completed in first 7 weeks post-FDA approval, exceeding internal expectations.
  • Reimbursement Breakthrough: 100% prior authorization approval rate, 35 VAC approvals secured.
  • Financial Strength: EUR 26 million capital raise provides 18-month cash runway.
  • Gross Margin Path: 80%+ achievable with Genio 2.2 launch in 2027.
  • Patient Impact: 50-54 year-old patients driving early adoption, no CCC contraindication.
EPS
Revenue

Revenue & Expenses

NYXH has released its 2025 Q3 earnings report, with revenue of 2.31M, reflecting a YoY change of 64.01%, and net profit of -27.67M, showing a YoY change of -45.55%. The Sankey diagram below clearly presents NYXH's revenue sources and cost distribution.

Key Indicators

Nyxoah (NYXH) key financial stats and ratios, covering profitability, financial health, and leverage.
Nyxoah (NYXH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Nyxoah (NYXH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Nyxoah (NYXH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Nyxoah (NYXH) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Nyxoah (NYXH) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield